Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$48.27M+54.0%-$66.42M+42.5%-$81.16M+39.6%-$91.99M+38.7%-$104.94M+29.2%
$799K+12.2%$822K+24.2%$812K+13.2%$812K+13.2%$712K-12.9%
$46.76M+60.0%$41.72M+50.0%$34.81M+34.4%$29.98M+26.3%$29.23M+36.3%
-$80.87M+34.7%-$65.89M+50.6%
$15.09M+661%$9.86M+529%$3.57M+139%$1.95M+22.5%$1.98M+48.4%
-$150.96M-20.9%-$146.22M-88.6%-$135.04M-599%
$8.03M-95.6%$143.39M-7.3%$144M-16.0%$142.08M-48.5%$182.45M-22.0%
-$15.36M-112%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Tarsus Pharmaceuticals, Inc. generate?
Tarsus Pharmaceuticals, Inc. (TARS) generated -$96.9M in operating cash flow over the trailing twelve months.
What is Tarsus Pharmaceuticals, Inc.'s free cash flow?
After $15.1M of capital expenditures, Tarsus Pharmaceuticals, Inc.'s free cash flow was -$104.4M over the trailing twelve months, down 2.6% year over year.
Where does Tarsus Pharmaceuticals, Inc.'s cash flow data come from?
Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.